Inflammation, Skin Patents (Class 514/886)
-
Patent number: 5736579Abstract: A class of substituted spiro compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula III: ##STR1## wherein n is a number selected from 0, 1 and 2; wherein R.sup.3 is methylsulfonyl or sulfamyl; and wherein R.sup.8 is selected from hydrido, fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, hydroxyl, mercapto, methylthio, ethylthio, cyano, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, trifluoromethoxy, hydroxymethyl, methoxymethyl and ethoxymethyl; or a pharmaceutically-acceptable salt thereof.Type: GrantFiled: November 18, 1994Date of Patent: April 7, 1998Assignee: G.D. Searle & Co.Inventors: David B. Reitz, Robert E. Manning, Horng-Chi Huang, Jinglin Li
-
Patent number: 5733881Abstract: Compounds of the formula I as well as methods for their preparation, their pharmaceutical preparations and their use. ##STR1## The compounds of formula I are useful in therapy, especially as analgesics and as immunosuppresive agents.Type: GrantFiled: August 22, 1995Date of Patent: March 31, 1998Assignee: Astra ABInventor: Peter Schiller
-
Patent number: 5733939Abstract: A method for reducing the inflammatory response in tissues of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.Type: GrantFiled: November 22, 1995Date of Patent: March 31, 1998Assignee: Alliance Pharmaceutical Corp.Inventors: Bradley Phillip Fuhrman, Stephen F. Flaim, Lynn Joanne Hernan, Frances Darey Nesti, Michele Cecile Papo, David Marc Steinhorn
-
Patent number: 5728685Abstract: Compounds and methods of making them having the following formula are described which bind to selectin receptors and thus modulate the course of inflammation, cancer and related diseases by modulating cell-cell adhesion events: ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, OH or lower alkyl (1-4C), or a lipophilic group such as a higher alkyl group (5-15C), alkylaryl or one or more additional saccharide residues;R.sup.3 is a negatively charged moiety including SO.sub.4.sup.2-, PO.sub.4.sup.2-, or related group;Y is H or lower alkyl (1-4C); andX is H or --CHR.sup.4 (CHOR.sup.1).sub.2 CHR.sup.5 OR.sup.1 wherein R.sup.4 and R.sup.5 are each independently H, lower alkyl (1-4C), or taken together result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S, and NR.sup.1 ;said five- or six-membered ring optionally substituted with one substituent selected from the group consisting of R.sup.1, CH.sub.2 OR.sup.1, OR.sup.Type: GrantFiled: June 6, 1995Date of Patent: March 17, 1998Assignee: Glycomed IncorporatedInventors: Saeed A. Abbas, Falguni Dasgupta, Darwin Asa, John H. Musser, Mina A. Nashed
-
Patent number: 5708025Abstract: Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.Type: GrantFiled: June 6, 1995Date of Patent: January 13, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Dvorit Samid
-
Patent number: 5705477Abstract: A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-.beta. which is activated by either a TGF-.alpha. or an EGF or both; and methods for administration. As another embodiment these active ingredients can be admixed with other (secondary) growth factors.Type: GrantFiled: July 5, 1994Date of Patent: January 6, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael B. Sporn, Anita B. Roberts
-
Patent number: 5702710Abstract: Novel pharmaceutically/cosmetically-active dibenzofuran compounds have the structural formula (I): ##STR1## wherein A is a radical having one of the formulae (IIa), (IIb) or (IIc): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.Type: GrantFiled: October 4, 1995Date of Patent: December 30, 1997Assignee: Centre International de Recherches Dermatologiques GaldermaInventors: Bruno Charpentier, Michele Vion, Bruno Bernard, Jean Maignan
-
Patent number: 5695771Abstract: Cosmetic and/or dermatological compositions containing a non-photocatalytic metal oxide and tocopherol and, optionally, a metal-inactivating complexing agent are effective for inhibiting the light-induced peroxidation of lipids, and in particular lipids of sebaceous origin such as squalene.Type: GrantFiled: October 26, 1995Date of Patent: December 9, 1997Assignee: L'OrealInventors: Boudiaf Boussouira, Quang Lan Nguyen
-
Patent number: 5686435Abstract: The invention pertains to vitamin D amide derivatives of formula (I). These novel 1.alpha.-hydroxy vitamin D derivatives and their 20-epi analogues comprise compounds of formula (I) and corresponding 5,6-trans isomers, where Y represents an alkylene or alkenylene group containing up to four carbon atoms; R.sup.1 and R.sup.2 independently represent a hydrogen atom or a lower alkyl or cycloalkyl group, or R.sup.1 R.sup.2 N-- represents a heterocyclic group; and R.sup.3 and R.sup.4 independently represent a hydrogen atom or an O-protecting group. Active compounds, in which R.sup.3 and R.sup.4 are hydrogen atoms or metabolically labile O-protecting groups exhibit potent cell modulating effect, but minimal effect on calcium metabolism.Type: GrantFiled: December 7, 1995Date of Patent: November 11, 1997Assignee: Research Institute for Medicine and ChemistryInventors: Robert Henry Hesse, Gaddam Subba Reddy, Sundara Katugam Srinivasasetty Setty
-
Patent number: 5686426Abstract: There is provided a novel series of O-carboxymethylated .alpha.- and .beta.-glycolipid compounds of the formula ##STR1## wherein R is an acyl residue of a fatty acid;R.sup.1 is --(CH.dbd.CH).sub.m --(CH.sub.2).sub.n --CH.sub.3 ;R.sup.2, R.sup.3, R.sup.4 R.sup.5 and R.sup.6 each are independently hydrogen, unsubstituted or substituted alkanoyl, arylalkyl or arylcarbonyl wherein said substituent is selected from halogen, C.sub.1-4 alkyl, trifluoromethyl, hydroxy and C.sub.1-4 alkoxy;R.sup.3, R.sup.4 and R.sup.6 each are independently --CH.sub.2 COOR.sup.7, provided at least two of the R.sup.3, R.sup.4 and R.sup.6 substituents are --CH.sub.2 COOR.sub.7 ;m is an integer of 0 or 1;n is an integer of from 5 to 14, inclusive; andR.sup.Type: GrantFiled: November 17, 1994Date of Patent: November 11, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Alain Martel, John J. Wright
-
Patent number: 5679660Abstract: A method of preparing an injectable pharmaceutical or veterinary composition which comprises either diclofenac or a salt thereof and 2-hydroxypropyl beta-cyclodextrin, or an inclusion complex of diclofenac or a salt thereof and 2-hydroxypropyl beta-cyclodextrin, includes the step of dissolving either the diclofenac or salt thereof and the 2-hydroxypropyl beta-cyclodextrin, or the inclusion complex, in water to form a solution, the water having been acidified to a pH such that the pH of the solution is from 6.0 to 8.5 inclusive, in the absence of a phosphate buffer. The composition so produced has good stability on storage.Type: GrantFiled: December 2, 1994Date of Patent: October 21, 1997Assignee: Farmarc Nederland BVInventors: Mark David Bodley, Lueta Ann Glintenkamp, Lawrence John Penkler, Michiel Coenraad Bosch van Oudtshoorn
-
Patent number: 5679667Abstract: Aminoalcohols N-acyl derivatives useful in the prevention and in the treatment of mammalian pathologies induced by mast cell degranulation in consequence of peripheral nerve noxae.Type: GrantFiled: October 21, 1994Date of Patent: October 21, 1997Assignee: Lifegroup S.P.A.Inventors: Francesco Della Valle, Silvana Lorenzi, Federica Della Valle
-
Patent number: 5674902Abstract: The present invention relates to a method of inhibiting a protein kinase C-mediated biological response, such as, hyperplasia. The method comprises administering to a mammal a non-tumor promoting 12-deoxyphorbol ester. Phorbol esters suitable for use in the method include 12-deoxyphorbol 13-monoesters wherein the ester is a formate, acetate, propionate, butyrate, pentanoate, hexanoate, benzoate or phenylacetate ester.Type: GrantFiled: May 26, 1995Date of Patent: October 7, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter M. Blumberg, Zoltan Szallasi
-
Patent number: 5674853Abstract: The present invention features saponin containing enteral formulations for treatment of infection and inflammation. These saponin containing formulations are particularly useful in conjunction with oils rich in .omega.3 polyunsaturated fatty acids such as fish oils and flax oil but also show benefits with .omega.6 rich oils such as borage oil, black currant seed oil, canola oil and rapeseed oil. These formulations may also contain a lignan from the sesamin family.Type: GrantFiled: March 7, 1995Date of Patent: October 7, 1997Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: R. Armour Forse, Sambasiva Chavali
-
Patent number: 5670142Abstract: A method for reducing the itch and the scarring associated with chicken pox is disclosed. The method entails applying a topical pharmaceutical formulation of papain, pancreatin or subtilisin to the skin proximate to the vesicles. To further reduce scarring, an antibiotic is applied with the papain, pancreatin or subtilisin. Compositions are provided in the form of solutions, lotions, ointments and salves containing papain, pancreatin or subtilisin and, optionally, a surfactant, an antibiotic and a penetration enhancer.Type: GrantFiled: July 8, 1996Date of Patent: September 23, 1997Assignee: Donald NeudeckerInventor: Stan Michael Rubin
-
Patent number: 5662903Abstract: Prophylactic and therapeutic agents for the prevention and treatment of viral-induced tumors and, in particular, compositions derived from an Aspergillus fermentation extract, and the use thereof, either directly or to prepare a medicament, for the prevention and treatment of viral-induced tumors in mammals. Such tumors include papilloma-induced tumors. The composition is topically administered.Type: GrantFiled: June 5, 1995Date of Patent: September 2, 1997Assignee: Genencor International, Inc.Inventors: Ernest W. Boyer, Robert L. Charles
-
Patent number: 5662902Abstract: Prophylactic and therapeutic agents for the prevention and treatment of viral-induced tumors and, in particular, compositions derived from an Aspergillus fermentation extract, and the use thereof, either directly or to prepare a medicament, for the prevention and treatment of viral-induced tumors in mammals. Such tumors include papilloma-induced tumors. The composition is topically administered.Type: GrantFiled: June 5, 1995Date of Patent: September 2, 1997Assignee: Genencor International, Inc.Inventors: Ernest W. Boyer, Robert L. Charles
-
Patent number: 5661020Abstract: Disclosed are pharmaceutical compositions containing low diol polyethylene glycol, covalently attached to superoxide and dismutase process of making the compositions. Also disclosed is a method of treatment of disease processes associated with the adverse effects on tissue of superoxide anions, such as ischemic events, reperfusion injury, trauma and inflammation.Type: GrantFiled: April 15, 1996Date of Patent: August 26, 1997Assignee: SanofiInventors: Robert A. Snow, David L. Ladd, Denton W. Hoyer
-
Patent number: 5658956Abstract: The present invention pertains to therapeutic bioadhesive-wound healing compositions useful for treating wounds and increasing the proliferation and resuscitation rate of mammalian cells. The compositions comprise a bioadhesive agent and a therapeutically effective amount of a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic bioadhesive-wound healing compositions may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the bioadhesive-wound healing compositions and the pharmaceutical products in which the compositions may be used.Type: GrantFiled: May 22, 1995Date of Patent: August 19, 1997Assignee: Warner-Lambert CompanyInventors: Alain Martin, Sau-Hung S. Leung
-
Patent number: 5648377Abstract: The present invention relates to novel formulations and combinations of lipophilic and hydrophilic antioxidants and the use thereof in the therapeutic, foodstuff, dietetic, and cosmetic fields. These formulations are based on the use of carotenoids, procarotenoids and derivatives thereof with polyphenols of catechic structures. Said formulations, containing a lipophilic antioxidant and an hydrophilic one, can be used in the prevention of physiopatological conditions related at least partially to an over-production of free radicals, particularly aging, atherosclerosis and cancer.Type: GrantFiled: June 5, 1995Date of Patent: July 15, 1997Assignee: Indena S.p.A.Inventors: Ezio Bombardelli, Paolo Morazzoni
-
Patent number: 5646156Abstract: The invention concerns the identification on eosinophils of the A3 adenosine receptor subtype and the blockade of said receptor in order to achieve inhibition of eosinophil activation and degranulation.Type: GrantFiled: April 25, 1994Date of Patent: July 8, 1997Assignee: Merck & Co., Inc.Inventors: Marlene A. Jacobson, Robert G. Johnson, Christopher A. Salvatore
-
Patent number: 5646128Abstract: Novel compounds which selectively inhibit adenosine kinase and methods of preparing adenosine kinase inhibitors are provided. Also provided are methods of treating various inflammatory conditions, including arthritis and SIRS, which may be ameliorated by increased local concentrations of adenosine using adenosine kinase inhibitors.Type: GrantFiled: December 1, 1994Date of Patent: July 8, 1997Assignee: Gensia, Inc.Inventors: Gary S. Firestein, Bheemarao G. Ugarkar, Leonard P. Miller, Harry E. Gruber, David A. Bullough, Mark D. Erion, Angelo J. Castellino, Clinton E. Browne
-
Patent number: 5631245Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.Type: GrantFiled: June 6, 1995Date of Patent: May 20, 1997Assignee: Biodynamics Pharmaceuticals, Inc.Inventor: Clairmont G. Drube
-
Patent number: 5629351Abstract: Disclosed herein is a novel fraction comprising a mixture of boswellic acids, wherein the fraction exhibits anti-inflammatory and antiulcerogenic activities. Also disclosed is a novel boswellic acid compound exhibiting anti-inflammatory, antiathritic and antiulcerogenic activities. Also disclosed is a process for isolating a boswellic acid fraction and individual boswellic acids therefrom.Type: GrantFiled: April 13, 1995Date of Patent: May 13, 1997Assignee: Council of Scientific & Industrial ResearchInventors: Subhash C. Taneja, Vijay K. Sethi, Kanaya L. Dhar, Randhir S. Kapil
-
Patent number: 5629347Abstract: Compounds of formula (I), and salts and prodrugs thereof, wherein Q is R.sup.9 CR.sup.10 R.sup.11 or CH.sub.2 R.sup.9 CR.sup.10 R.sup.11 where R.sup.9 is H or OH and R.sup.10 and R.sup.11 are optionally substituted phenyl, optionally substituted benzyl, C.sub.5-7 cycoalkyl or (C.sub.5-7 cycloalkyl)methyl; R.sup.1 and R.sup.2 are H, optionally substituted C.sub.1-6 alkyl, optionally substituted phenyl(C.sub.1-4 alkyl), C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, COR.sup.a, COOR.sup.a, COC.sub.1-6 alkylhalo, COC.sub.1-6 alkylNR.sup.a R.sup.b, CONR.sup.12 C.sub.1-6 alkylCONR.sup.a R.sup.b, CONR.sup.a R.sup.b, or SO.sub.2 R.sup.a, or R.sup.1 and R.sup.2 together form a chain (CH.sub.2).sub.q optionally substituted by oxo where one methylene group may optionally be replaced by O or NR.sup.x ; R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; R.sup.4 is optionally substituted phenyl(C.sub.1-3 alkyl); X and Y are H, or X and Y together are .dbd.O; and Z is O, S, or NR.sup.7 ; are tachykinin antagonists.Type: GrantFiled: December 22, 1993Date of Patent: May 13, 1997Assignee: Merck Sharp & Dohme Ltd.Inventors: Christopher J. Swain, Martin R. Teall, Brian J. Williams
-
Patent number: 5627216Abstract: A composition made from eggplant for the treatment of hemorrhoids is disclosed. A composition which effectively reduces swelling and pain in the anal area is formed by mixing powdered eggplant leaves and boiling virgin olive oil in a covered container for approximately 30 minutes.Type: GrantFiled: April 7, 1995Date of Patent: May 6, 1997Inventor: George D. Papadopoulos
-
Patent number: 5624938Abstract: This invention provides a pharmaceutical composition which comprises an amount of chloroquine effective to block MHC Class I recycling and an amount of a CD8+ T cell stimulatory agent effective to stimulate proliferation of CD8+ T cells to a concentration such that the resulting CD8+ T cells kill CD4+ T cells, and a pharmaceutically acceptable carrier.This invention provides a method for treating an autoimmune disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the autoimmune disease.This invention provides a method for treating cutaneous lymphoma disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the cutaneous lymphoma disease.This invention provides a method for treating rheumatoid arthritis in a subject which comprises administering to the subject an amount of the pharmaceutical composition of chloroquine and a CD8+ T cell stimulatory agent effective to treat rheumatoid arthritis.Type: GrantFiled: July 18, 1994Date of Patent: April 29, 1997Assignee: The Trustees of Columbia University in the City of New YorkInventor: Benvenuto G. Pernis
-
Patent number: 5624673Abstract: The invention relates to the use of an extract of prunella or at least one prunella saponin. This extract or this saponin is used for the preparation of a cosmetic or pharmaceutical and/or dermatological composition. Said composition makes it possible to regulate the renewal and differentiation of the keratinocytes and has an anti-aging activity, an anti-inflammatory activity, especially in inflammations caused by ultraviolet radiation, or an anti-allergic or anti-free-radical activity. It also enables the epidermis of normal skin to be kept in good condition, especially by maintaining the functional role of the skin, in particular as a protective barrier, and makes it possible to prevent or treat dry skin, especially ichthyotic skin, and to treat psoriasis.Type: GrantFiled: December 6, 1993Date of Patent: April 29, 1997Assignee: LYMH RechercheInventors: Frederic Bonte, Alain Meybeck, Marc Dumas
-
Patent number: 5616458Abstract: The present invention provides for the use of Tripterygium wilfordii Hook F extracts and purified components thereof in the treatment of inflammation or an immune disorder with concomitant lack of steroidal effect. Extracts of this plant (T2) bound to the glucocorticoid receptor and competitively inhibited glucocorticoid mediated cellular processes, such as dexamethasone binding to the glucocorticoid receptor, glucocorticoid mediated activation of target genes, dexamethasone dependent cellular growth, with concomitant inhibition of cyclooxygenase-2 induction and inflammatory processes such as the production of prostaglandin E.sub.2. The T2 extract components triptolide and tripdiolide were effective inhibitors. The particular advantage provided by the methods herein is the treatment or prevention of inflammation and the concomitant lack of steroidal agonist effects and NSAID side effects. Conditions treatable by the present methods include inflammation and immune disorders including autoimmune disease.Type: GrantFiled: May 31, 1995Date of Patent: April 1, 1997Assignee: Board of Regents, University of TX SystemInventors: Peter E. Lipsky, Xue-Lian Tao, Jian Cai, William J. Kovacs, Nancy J. Olsen
-
Patent number: 5616324Abstract: A synergistic mixture particularly suitable for the treatment of animals whic consists of at least two of the group consisting of DL.Phenylalanine, Ruta Graveolans and Corydali Bulbosa together with a carrier to make up a required volume, the mixture having a pro-inflammatory effect which accelerates the healing process of inflammation. It is preferred that there is provided mixture of DL.Phenylalanine with one product selected from the group of Ruta Graveolans and Corydalis Bulbosa. In a specific form, the mixture also includes Nicotinic Acid.Type: GrantFiled: May 31, 1995Date of Patent: April 1, 1997Inventors: Antoinette Foster, Don Foster
-
Patent number: 5612378Abstract: The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: ##STR1## wherein each R.sup.1 is independently one of alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;each R.sup.2 and R.sup.3 is independently one of hydrogen, alkyl, aryl or arylalkyl;Y is a bond, or is one of --(CH.sub.2).sub.p --, cycloalkyl, aryl or C.sub.2-10 heterocycle; andm, n and p are each independently 1 to 10.Type: GrantFiled: June 6, 1995Date of Patent: March 18, 1997Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Lu Tianbao, Richard M. Soll
-
Patent number: 5605923Abstract: Novel cyclohexene-ylidene derivatives of formula (I) are described herein. These compounds inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; they are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV and are therefore useful in the treatment of disease states in need of mediation or inhibition thereof.Type: GrantFiled: September 29, 1994Date of Patent: February 25, 1997Assignee: SmithKline Beecham CorporationInventors: Siegfried B. Christensen, IV, Cornelia J. Forster
-
Patent number: 5601806Abstract: Taurine analogues are used for scavenging active oxygen compounds and preventing and minimizing damage to the skin from ultraviolet rays. The taurine analogues have the following formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification.Type: GrantFiled: September 20, 1994Date of Patent: February 11, 1997Assignee: Sogo Pharmaceutical Company LimitedInventors: Manabu Katsumata, Keiko Kiuchi, Tomoyasu Tashiro, Saburo Uchikuga
-
Patent number: 5599788Abstract: A method of producing recombinant transforming growth factor .beta.-induced H3 protein and the use of this protein to accelerate wound healing. H3 promoted adhesion of human dermal fibroblasts to tissue culture plastic. The protein is applied directly to a wound or is used to promote adhesion and spreading of dermal fibroblasts to a solid support such as a nylon mesh which is then applied to the wound. In addition, CHO cells expressing H3 inhibited tumor cell growth.Type: GrantFiled: July 1, 1994Date of Patent: February 4, 1997Assignee: Advanced Tissue SciencesInventors: Anthony F. Purchio, Richard LeBaron
-
Patent number: 5599558Abstract: A method of making a platelet releasate product is disclosed involving performing an assay on a platelet releasate sample for a component of the releasate and forming platelet releasate product by comparing the assay results to a predetermined range of amounts of the component to be contained in the product. A method of treatment of tissue is disclosed involving the topical application of such product.Type: GrantFiled: October 25, 1994Date of Patent: February 4, 1997Assignee: Curative Technologies, Inc.Inventors: Richard H. Gordinier, Ronald G. Duff, Dawn D. Newmann
-
Patent number: 5599551Abstract: This invention relates to an article of manufacture comprising an aqueous gel containing a selected zinc salt contained within a deformable plastic-walled tubular container, for convenient and consistent use as a topical genital lubricant during acts of sexual intercourse. The zinc salt must be organic, water-soluble, and have substantial dissociation rates to release divalent zinc ions. Suitable zinc salts include zinc acetate, zinc propionate, zinc butyrate, zinc formate, zinc gluconate, zinc glycerate, zinc glycolate, and zinc lactate. The gel must also contain a thickening agent (such as chemically treated cellulose) and a lubricating agent (such as glycerin), and it must be free of heparin, dextran sulfate, or any other anti-coagulant or other component which poses a substantial risk of adverse effects if the lubricant is used frequently and repeatedly over a period of months or years.Type: GrantFiled: December 22, 1994Date of Patent: February 4, 1997Inventor: Patrick D. Kelly
-
Patent number: 5589179Abstract: Cosmetic and/or dermatological compositions containing a non-photocatalytic metal oxide and tocopherol and, optionally, a metal-inactivating complexing agent are effective for inhibiting the light-induced peroxidation of lipids, and in particular lipids of sebaceous origin such as squalene.Type: GrantFiled: March 13, 1995Date of Patent: December 31, 1996Assignee: L'orealInventors: Boudiaf Boussouira, Quang L. Nguyen
-
Patent number: 5589509Abstract: A composition comprises a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites), together with a drug that taken alone has a side-effect of sensitizing the skin to light, in particular a porphyrin or tetracycline or Benoxaprofen, alone or in a pharmaceutically acceptable diluent or carrier, the composition reducing that sensitization.Type: GrantFiled: March 6, 1996Date of Patent: December 31, 1996Assignee: Efamol LimitedInventor: David F. Horrobin
-
Patent number: 5589514Abstract: Compounds of formula I, ##STR1## wherein the substituents R.sub.1 -R.sub.4 and a have the given meanings and show an activity against inflammatory conditions.Type: GrantFiled: May 19, 1995Date of Patent: December 31, 1996Assignee: Hoechst AktiengesellschaftInventors: Ramachandra G. Naik, Vilas N. Mumbaikar, Rangarajan Vasumathy, Aftab D. Lakdawala, Mandakini V. Shirole, Bansi Lal, Jurgen Blumbach, Klaus U. Weithmann, Robert R. Bartlett
-
Patent number: 5587364Abstract: Methods of treating inflammatory diseases in an animal by administering to the animal an effective amount of a polymeric acetylated mannan derivative of aloe origin.Type: GrantFiled: June 5, 1995Date of Patent: December 24, 1996Assignee: Carrington Laboratories, Inc.Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
-
Patent number: 5576330Abstract: The new use of a compound of formula (I) ##STR1## wherein Y is a bicyclic ring selected from naphthalene, tetralin, quinoline, isoquinoline and indole;n is zero or an integer of 1 to 3;R.sub.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl;R.sub.2 is hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, cyano, carboxy, nitro, or NHR, wherein R is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.4 is hydrogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.2 -C.sub.6 alkanoyloxy, carboxy, nitro or NHR, wherein R is as defined above;R.sub.5 is hydrogen, C.sub.1 -C.sub.6 alkyl or halogen; or a pharmaceutically acceptable salt thereof;and wherein when Y is naphthalene then n is zero or an integer of 1 to 3, whereas when Y is tetralin, quinoline, isoquinoline or indole then n is zero, 1 or 2; and wherein when the bicyclic ring Y is naphthalene, quinoline, isoquinoline or indole, then each of the substituents OR.sub.1, R.sub.Type: GrantFiled: December 12, 1994Date of Patent: November 19, 1996Assignee: Farmitalia Carlo Erba S.r.l.Inventors: Franco Buzzetti, Antonio Longo, Maria G. Brasca, Fabrizio Orzi, Angelo Crugnola, Dario Ballinari, Mariangela Mariani
-
Patent number: 5569649Abstract: A method of treating inflammation in a subject by administering a therapeutically effective amount of a compound having the structure: ##STR1## where R.sub.1 to R.sub.4 are the same or different and are each selected from the group consisting of H, an alkylacyl group, an arylacyl group, or a C-1-linked saccharide.Type: GrantFiled: June 14, 1994Date of Patent: October 29, 1996Assignee: Phytopharm (NA) N.V.Inventors: Anthony C. Allison, Carl F. de Vos Albrecht, Petrus B. Kruger, Marthinus J. van der Merwe
-
Patent number: 5567590Abstract: Disclosed is a method for diagnosing inflammation in an animal which includes analyzing cells to assess glucocorticoid receptor binding affinity or glucocorticoid receptor number. A low binding affinity and high receptor number are each indicative of inflammation. Also disclosed is a method for treating inflammation in an animal, which inflammation causes glucocorticoid receptor alteration which includes suppressing the activity or expression of cytokines which, in the absence of suppression, alter glucocorticoid receptors. Also disclosed are methods for identifying Type II glucocorticoid receptor binding abnormality and for distinguishing Type I glucocorticoid receptor binding abnormalities from Type II. Further disclosed are treatments for steroid-resistant inflammatory disorders induced by IL-2 and IL-4 which are associated with glucocorticoid receptor binding abnormalities. The treatment includes administering an agent which is an IL-2 suppressor and/or an IL-4 suppressor.Type: GrantFiled: January 6, 1994Date of Patent: October 22, 1996Assignee: National Jewish Center for Immunology and RespiratoryInventors: Donald Y. M. Leung, Stanley J. Szefler, Joseph D. Spahn
-
Patent number: 5565448Abstract: The present invention relates to the treatment and prevention of conditions wherein protein Kinase C inhibition is indicated.Type: GrantFiled: August 25, 1994Date of Patent: October 15, 1996Assignee: SmithKline Beecham CorporationInventors: Ponnal Nambi, Ashok D. Patil
-
Patent number: 5560935Abstract: The present invention provides a physiologically active substance which inhibits plasma kallikrein production, improves peripheral blood flow, and exhibits analgesic, antiinflammatory and antiallergic action. The physiologically active substance of the present invention is prepared by activating various animals or animal tissues by means of inoculation with virus or tumor cells which act as a stressor, and then extracting the effective factor from the activated tissues. The substance exhibits a pharmacological action of inhibiting activity for production of plasma kallikrein and recovering and normalizing abnormal functions which are associated with the diseased state. The physiologically active substance and pharmaceutical compositions of the present invention exhibit excellent regulating activity for biofunctions. They provide recovery and normalization of abnormal functions in living organisms in various diseased states.Type: GrantFiled: September 27, 1994Date of Patent: October 1, 1996Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Jin-emon Konishi, Giichi Hamada
-
Patent number: 5559109Abstract: A method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma, inflammation or shock by administering an effective amount of a PAF antagonist of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5 ; R.sup.5 is an unsubstituted or substituted C.sub.6 -C.sub.14 carbocyclic aryl of an aromatic heterocyclic having from 5 to 14 ring atoms, of which from 1 to 5 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group being unsubstituted or substituted; R.sup.3 is hydrogen, a C.sub.1 -C.sub.6 alkyl, cyano, or --R.sup.5 ; X is oxygen or sulfur; A is a 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B is a C.sub.1 -C.sub.6 alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is an unsubstituted or substituted phenyl group.Type: GrantFiled: October 7, 1994Date of Patent: September 24, 1996Assignee: Sankko Company, LimitedInventors: Norio Nakamura, Nobuyuki Ohkawa, Takeshi Oshima, Masaaki Miyamoto, Yasuteru Iijima
-
Patent number: 5559103Abstract: The present invention relates to bivalent sialyl Lewis X saccharide compounds that inhibit cellular binding to a selectin receptor. Pharmaceutical compositions containing a compound of Formula I, and processes for making and using the same are disclosed. A contemplated bivalent sialyl Lewis X saccharide compound has a structure that corresponds to Formula I, below, ##STR1## wherein R is a directly linked divalent monosaccharide unit; Y is selected from the group consisting of C(O), SO.sub.2, HNC(O), OC(O) and SC(O);R.sup.2 is selected from the group consisting of a C.sub.1 -C.sub.6 hydrocarbyl, an aryl, a substituted aryl and a phenyl C.sub.1 -C.sub.3 alkylene group, wherein an aryl group has one six-membered aromatic ring or two fused six-membered aromatic rings, which ring or rings are hydrocarbyl, monoazahydrocarbyl, or diazahydrocarbyl rings, and a substituted aryl group is a before-mentioned aryl group having a substituent selected from the group consisting of halo, trifluoromethyl, nitro, C.sub.1 -C.Type: GrantFiled: July 20, 1994Date of Patent: September 24, 1996Assignee: Cytel CorporationInventors: Federico C. A. Gaeta, Shawn A. DeFrees
-
Patent number: 5545673Abstract: A method is disclosed for reducing the risk of infection by sexually transmitted viruses. This method involves spreading a lubricant fluid containing a selected zinc salt across the surfaces of the penis or vagina, before intercourse, in a manner that causes the lubricant to coat and remain in contact with the genital surfaces throughout intercourse. The zinc salt should be organic, water-soluble, non-irritating, physiologically acceptable, and have a high rate of dissociation, which allows it to release substantial quantities of divalent zinc ions. Suitable zinc salts include zinc acetate, zinc propionate, zinc butyrate, zinc formate, zinc gluconate, zinc glycerate, zinc glycolate, and zinc lactate. A preferred carrier fluid comprises a lubricant gel, which also contains water, a thickening agent (such as chemically treated cellulose) and a lubricating agent (such as glycerin).Type: GrantFiled: January 3, 1995Date of Patent: August 13, 1996Inventor: Patrick D. Kelly
-
Patent number: 5532215Abstract: The present invention provides a method for inhibiting viral proliferation by preventing or inhibiting viral replication or killing the viruses on contact. Viral replication is prevented or inhibited through the use of serine protease inhibitors, their analogs, salts, conjugates or derivatives.Type: GrantFiled: October 3, 1994Date of Patent: July 2, 1996Inventors: John Lezdey, Allan Wachter
-
Patent number: 5531992Abstract: A low molecular weight vegetable composition comprising a seed of Milk Thistle which are heated with far infrared rays, for example, using a vessel comprising ceramics and then brewed with brewing bacteria such as "Koji" fungus, digestive enzyme, protein hydrolase or a precursor giving said enzyme or said protein hydrolase.Type: GrantFiled: June 2, 1994Date of Patent: July 2, 1996Assignee: Kozo NiwaInventors: Hiroko Yamazaki, Masahiro Kuroda, Kozo Niwa